Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
131.19
+0.31 (+0.24%)
Official Closing Price
Updated: 7:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation
March 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression
March 17, 2022
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial
March 16, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces KEYLYNK-010 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination with LYNPARZA® (olaparib) in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility
March 15, 2022
From
Merck & Co., Inc.
Via
Business Wire
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
February 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Shares Environmental, Social & Governance Priorities and Strategy
February 23, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Event to Discuss Long-Term Environmental, Social & Governance Priorities
February 17, 2022
SOURCE: Merck & Co., Inc.
Via
3BL Media
Merck Announces New Leadership for Human Health Business
February 16, 2022
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Status
February 14, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Event to Discuss Long-Term Environmental, Social & Governance Priorities
February 14, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
Pivotal Phase 3 Data for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine
February 09, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States
February 08, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck to Participate in the Guggenheim Oncology Conference 2022
February 04, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results
February 03, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies
January 28, 2022
From
Merck & Co., Inc.
Via
Business Wire
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
January 27, 2022
From
Merck & Co., Inc.
Via
Business Wire
R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments
January 27, 2022
Palm Beach, FL – January 27, 2022 – FinancialNewsMedia.com News Commentary – According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018,...
Via
FinancialNewsMedia
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Merck Announces Second-Quarter 2022 Dividend
January 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Provides U.S. and Japan Regulatory Update for Gefapixant
January 24, 2022
From
Merck & Co., Inc.
Via
Business Wire
Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer
January 20, 2022
Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine
January 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Frank Clyburn to Leave Merck
January 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
January 18, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
January 18, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Announce Supply Agreement With UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
January 18, 2022
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities
January 10, 2022
SOURCE: Merck & Co., Inc.
Via
3BL Media
Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression
January 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3
January 07, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.